https://scholars.lib.ntu.edu.tw/handle/123456789/468895
標題: | Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute | 作者: | HSIN-AN HOU MING YAO JIH-LUH TANG YIN-KAI CHEN BOR-SHENG KO Huang S.-Y. HWEI-FANG TIEN HSIU-HAO CHANG MENG-YAO LU TING TSE LIN Lin K.-H. Hsiao C.-H. CHUNG-WU LIN YAO-CHANG CHEN |
公開日期: | 2009 | 卷: | 43 | 期: | 4 | 起(迄)頁: | 315-321 | 來源出版物: | Bone Marrow Transplantation | 摘要: | EBV-induced post transplant lymphoproliferative disorder (PTLD) continues to be a major complication after transplantation. Between January 1993 and April 2006, 12 cases of B-cell lymphoproliferative disorder were identified among 577 patients after allogeneic hematopoietic SCT (HSCT) with an overall incidence of 2.51% at 1 year. Grades II-IV acute GVHD, CMV antigenemia and the use of antithymocyte globulin (ATG) were independent risk factors for PTLD. At diagnosis, all of the tumors were CD20-positive and 11 (92%) were EBV-encoded RNA (EBER)-positive. Of the 12 patients with B-cell lymphoproliferative disorder, 8 had pulmonary involvement and 10 had extranodal involvement. Eleven patients received weekly rituximab therapy at a dose of 375 mg/ m2; the median interval between the onset of symptoms and rituximab therapy was 6 days. The overall mortality rate was 92% and seven (64%) of the deaths were directly attributable to disseminated PTLD within days or weeks of presentation. In our series, pulmonary PTLD followed an extremely aggressive course and poor response to current therapy, even though rituximab was included in the therapeutic regimens. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-61449101655&doi=10.1038%2fbmt.2008.325&partnerID=40&md5=98f39862f37fa9a83ce146253fe6f593 https://scholars.lib.ntu.edu.tw/handle/123456789/468895 |
ISSN: | 0268-3369 | DOI: | 10.1038/bmt.2008.325 | SDG/關鍵字: | cyclosporin A; methotrexate; rituximab; thymocyte antibody; virus antigen; virus RNA; adult; allogeneic hematopoietic stem cell transplantation; article; B cell lymphoma; child; clinical article; Cytomegalovirus; Epstein Barr virus; female; graft versus host reaction; human; lung disease; lymphoproliferative disease; male; mortality; outcome assessment; post transplant lymphoproliferative disease; priority journal; prognosis; risk factor; Adolescent; Adult; Antibodies, Monoclonal; Child; Child, Preschool; Cohort Studies; Epstein-Barr Virus Infections; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lung Diseases; Lymphoproliferative Disorders; Male; Middle Aged; Multivariate Analysis; Risk Factors; Transplantation, Homologous; Treatment Outcome; Young Adult |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。